TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6368491
Drug: TNI or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNI or combined modality treatment
Study: 30199273
Drug: Less sensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less sensory conflict games (e.g., third‐person platformer games, space and flight simulator games)
Study: 24971923
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy for 30 days
Study: 10432134
Drug: Topical estradiol
Normalized name: estradiol Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estradiol (E2) cream and pelvic muscle biofeedback training
Study: 10432134
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and pelvic muscle biofeedback training
Study: 10432134
Drug: Topical estradiol
Normalized name: estradiol Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estradiol (E2) cream and sham biofeedback
Study: 10432134
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and sham biofeedback
Study: 1844356
Drug: Topical mechlorethamine
Normalized name: mechlorethamine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mechlorethamine hydrochloride in aqueous vehicle
Study: 1844356
Drug: Topical mechlorethamine
Normalized name: mechlorethamine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mechlorethamine hydrochloride in ointment vehicle
Study: 24449682
Drug: Budesonide (1
Normalized name: budesonide (11.beta.,16.alpha.(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1 mg) via mucosal atomization device (MAD) twice a day for 60 days
Study: 24449682
Drug: Budesonide via
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide via impregnated nasal saline irrigation (INSI) twice a day for 60 days
Study: 17571283
Drug: Advicor (1000/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advicor (1000/20 mg)
Study: 17571283
Drug: Niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER (1000 mg)
Study: 17571283
Drug: Niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER (1000 mg) + Lovastatin (20 mg)
Study: 10743483
Drug: High-carbohydrate breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate breakfast with red pepper (10 g)
Study: 10743483
Drug: Mixed diet
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed diet with red-pepper appetizer (6 g)
Study: 8535554
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, aspirin) 75 mg daily
Study: 8535554
Drug: Calcium antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist, felodipine, 5 mg once daily
Study: 2191582
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg isosorbide‐5‐mononitrate (IS‐5‐MN) in sustained-release (SR) form
Study: 2191582
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg isosorbide‐5‐mononitrate (IS‐5‐MN) in sustained-release (SR) form
Study: 6999981
Drug: High-dose ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ampicillin (150 mg/kg per day)
Study: 6999981
Drug: Low-dose ampicillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ampicillin (50 mg/kg per day)
Study: 20524462
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (10 mmol of magnesium sulphate dissolved in 100 ml of saline solution infused intravenously over 4 hours, for 3 days)
Study: 17496236
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (5 mg/day) for 2 years
Study: 7833098
Drug: Tropisetron 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.20 mg/kg or more
Study: 2971708
Drug: Inhaled VIP
Normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled VIP (70 micrograms)
Study: 2971708
Drug: Propranolol (provocative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (provocative dose)
Study: 24019429
Drug: School-based water
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based water treatment, hygiene, and sanitation program
Study: 19608353
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments for marijuana dependence
Study: 14509461
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical ketorolac)
Study: 9390478
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral hygiene with 1100-ppm fluoride toothpaste and 2% NaF treatment
Study: 1493344
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (50 micrograms in 1 ml preservative-free normal saline)
Study: 26758438
Drug: Regular rheumatologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular rheumatologic therapy (Control)
Study: 18518694
Drug: Antibiotic-impregnated shunt
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated shunt catheters (AISCs)
Study: 10615723
Drug: Alcohol Behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Behavioral Couples Therapy (ABCT)
Study: 8546437
Drug: Magnesium (600
Normalized name: magnesium oxide 348 mg magnesium (600 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (600 mg/day) supplementation
Study: 8546437
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g/day) supplementation
Study: 2039705
Drug: MMM (mitozantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMM (mitozantrone 8 mg m‐2 i.v. q 3 weekly, methotrexate 35 mg m‐2 i.v. q 3 weekly, mitomycin‐C 8 mg m‐2 i.v. q 6 weekly)
Study: 2039705
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 100 mg orally, days 1‐14, methotrexate 35 mg m‐2 i.v., days 1 and 8, 5‐FU 1,000 mg i.v., days 1 and 8, q 4 weekly)
Study: 28346570
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 (10-30 g/day)
Study: 28346570
Drug: Lactulose (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (10-30 g/day)
Study: 23400747
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) 5 mg followed by LEX 500 mg
Study: 23400747
Drug: Cephalexin (LEX)
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (LEX) 500 mg alone
Study: 23400747
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CXM) 500 mg alone
Study: 20592663
Drug: Once-daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lithium carbonate
Study: 20592663
Drug: Twice-daily lithium
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily lithium carbonate
Study: 7661538
Drug: L-ornithine 8-vasopressin
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine 8-vasopressin at a concentration of 0.01 IU/ml chilled saline
Study: 28549309
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (SC) via single-use injection device (SID)
Study: 28549309
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (SC) via hand-held syringe
Study: 28549309
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (IV)
Study: 24448345
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks plus methotrexate (MTX)
Study: 23653934
Drug: Combined probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined probiotic bifiform (Ferrosan) containing Bifidobacterium longum 107, Enterococcus faecium 107 as one capsule t.i.d. for 14 days, along with basic therapy (mesim forte as one tablet t.i.d., no-spa, 40 mg, t.i.d.)
Study: 23653934
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy in combination with placebo
Study: 9164774
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg of zinc as zinc sulfate daily for 7 months)
Study: 7958144
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinylestradiol + 75 micrograms gestodene (EE+G)
Study: 7958144
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (EE+D and EE+G)
Study: 3332568
Drug: Intravenous miconazole
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous miconazole
Study: 30865526
Drug: comparators (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparators (placebo, sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg)
Study: 22129843
Drug: Psilocybin 20
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 20 mg/70 kg
Study: 22129843
Drug: Psilocybin 30
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 30 mg/70 kg
Study: 21674151
Drug: Psilocybin (ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (ascending dose sequence)
Study: 21674151
Drug: Psilocybin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (20 and 30 mg/70 kg)
Study: 21674151
Drug: Psilocybin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (all doses)
Study: 18320185
Drug: FM‐VP4 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM‐VP4 400 mg/day
Study: 18320185
Drug: FM‐VP4 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM‐VP4 100 mg/day
Study: 18320185
Drug: FM‐VP4 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM‐VP4 200 mg/day
Study: 18320185
Drug: FM‐VP4 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM‐VP4 800 mg/day
Study: 8640040
Drug: Wheat-salt solution
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat-salt solution (WSS)
Study: 8640040
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organization recommended glucose-oral rehydration salts (G-ORS)
Study: 26824413
Drug: Ceftriaxone (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (dosage and duration not specified)
Study: 25225746
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose erythropoietin (400 IU/kg)
Study: 8508427
Drug: Modified FAMTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FAMTX treatment (5-fluorouracil, doxorubicin, methotrexate at 1000 mg/m2)
Study: 3330186
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (2.35 mg x 2, 120 min apart)
Study: 3330186
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (6 mg/kg followed by 0.5 mg/kg/hr infusion)
Study: 3330186
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulised salbutamol and intravenous aminophylline
Study: 29498924
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (RE)
Study: 29498924
Drug: Sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 800 mg/d
Study: 20577147
Drug: i.v. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection of Escherichia coli endotoxin (LPS; 2 ng/kg)
Study: 10754477
Drug: GHRH(1-29)NH2 (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH(1-29)NH2 (incremental doses)
Study: 8831308
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine, 3 mL of 0.5% spinal bupivacaine in 8% dextrose
Study: 8831308
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine, 2 mL of the 0.5% spinal bupivacaine + 1 mL saline
Study: 8831308
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg bupivacaine, 1.5 mL of the 0.5% spinal bupivacaine + 1.5 mL saline
Study: 8831308
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bupivacaine, 1 mL of the 0.5% spinal bupivacaine + 2 mL saline
Study: 20691130
Drug: enteric-coated lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated lactoferrin (eLF) 300 mg/d
Study: 18467726
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha (300 microg) administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy
Study: 16964522
Drug: Hydrochlorothiazide (HCT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT; 25 mg) monotherapy
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Enalapril (10 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Candesartan (8 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Amlodipine (5 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Propranolol (80 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Bisoprolol (5 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Diclofenac (50 mg)
Study: 16964522
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + Rofecoxib (25 mg)
Study: 10714840
Drug: Intraperitoneal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal lidocaine (200 mg in 200 ml saline)
Study: 10714840
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml saline)
Study: 8833706
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (TU I)
Study: 8833706
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with amino acids infusion (TU II)
Study: 8833706
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with heparin infusion (TU III)
Study: 26960245
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg tiotropium (2 puffs of 2.5 μg)
Study: 26960245
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg tiotropium (2 puffs of 1.25 μg)
Study: 26960245
Drug: Both tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tiotropium doses
Study: 25034562
Drug: Ustekinumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (180 mg at week 0 followed by 90 mg every 8 weeks)
Study: 25034562
Drug: Golimumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (200 mg at week 0 followed by 100 mg every 4 weeks)
Study: 16555581
Drug: pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15 mg/day)
Study: 12439788
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg once-daily + diet
Study: 12439788
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once-daily + diet
Study: 1971591
Drug: Xamoterol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol, 200 mg b.d.
Study: 1971591
Drug: Digoxin, 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin, 0.125 mg b.d. or t.d.
Study: 7198463
Drug: Plafibride (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plafibride (1600 mg/d)
Study: 7198463
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 1600 mg/d)
Study: 15661224
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) on days 1 and 8 and carboplatin AUC 4 on day 1 every 21 days for up to six cycles
Study: 2112616
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg on day 3 and 25 mg on day 6)
Study: 7451151
Drug: Penicillin and
Normalized name: Benzathine benzylpenicillin and procaine benzylpenicillin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin and probenecid (4 million IU depot penicillin i.m. + 1 g probenecid orally)
Study: 7451151
Drug: Probenecid given
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid given 30 min prior to penicillin administration
Study: 26341878
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg) plus control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Study: 26341878
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Study: 23633146
Drug: Doxylamine hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine hydrogen succinate 12.5 mg
Study: 23633146
Drug: Doxylamine hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine hydrogen succinate 25 mg
Study: 23633146
Drug: Doxylamine hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine hydrogen succinate 12.5 mg vs 25 mg
Study: 21307137
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (ExQW) 2 mg for 24 weeks
Study: 21307137
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily (ExBID) 5 μg for 4 weeks followed by 10 μg for 20 weeks
Study: 19824074
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with low-dose peginterferon
Study: 15265162
Drug: oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral alfacalcidol 0.25 microg daily
Study: 15265162
Drug: oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral alendronate 5 mg daily
Study: 15265162
Drug: nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray calcitonin 200 IU/day
Study: 9365147
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg glyceryl trinitrate
Study: 1804605
Drug: Nylestriol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 2 mg every 2 weeks for 1 year
Study: 1804605
Drug: Nylestriol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 2 mg every 2 weeks for 1 year with medroxyprogesterone acetate 6 mg daily for 7 days at the end of treatment
Study: 6321282
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran 18 g/day
Study: 6321282
Drug: Placebo 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 18 g/day
Study: 31655571
Drug: Treatment-as-usual control.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control.
Study: 27876358
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG; 400mg/kg/day for 5 days)
Study: 25802345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin B-12 and folic acid
Study: 23232095
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg (four tablets) single dose
Study: 23232095
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg 12‐hourly x two doses
Study: 23232095
Drug: 1,400 mg
Normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,400 mg (eight tablets) single dose
Study: 18551121
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (0.05 g/kg fat-free mass)
Study: 12455450
Drug: Methimazole (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (10-20 mg per day)
Study: 10483893
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with oral glutamine supplementation of 30 g/d
Study: 10483893
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with conventional glutamine-free amino acid solution
Study: 10483893
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of normal food
Study: 8738682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol 800 mg plus codeine 60 mg